Intensive Lipid Reduction and Proinflammatory Markers in the MODEST Study

Basit Öğe Kaydı
dc.contributor.authorKanat, Mustafa
dc.contributor.authorYildiz, Ozcan
dc.contributor.authorTunckale, Ayd N.
dc.contributor.authorCeyhan, Banu Ozturk
dc.contributor.authorKaragoz, Yalcin
dc.contributor.authorAltuntas, Yuksel
dc.contributor.authorOguz, Aytekin
dc.date.accessioned2024-09-25T19:56:23Z
dc.date.available2024-09-25T19:56:23Z
dc.date.issued2010
dc.departmentAbant İzzet Baysal Üniversitesien_US
dc.description.abstractObjective: Statin therapy is well known to reduce inflammatory markers such as tumor necrosis factor-alpha (TNF-alpha), interleukin 6 (IL-6), high-sensitivity C-reactive protein (hsCRP). However, whether this relationship is maintained in the setting of targeting very low levels of LDL (<70 mg dl) in patients with type 2 diabetes has not been clearly established. Materials and Methods: We measured hsCRP, IL-6, and TNF-alpha in 43 subject enrolled into the multicenter, open-label, crossover prospective study evaluating the effects of lipid-lowering treatment on steroid synthesis in patients with type 2 diabetes (MODEST study). Subjects with diabetes and coronary artery disease were treated with 80 mg of atorvastatin for 12 weeks. The effect of treatment on pro-inflammatory markers was assessed after 12 weeks. Results: High-dose atorvastatin treatment significantly reduced the plasma levels of IL-6 and hsCRP (p<0.05, p<0.001, respectively), but not of TNF-alpha (p=0.051). Conclusion: Atorvastatin treatment targeting very low LDL-cholesterol level reduced the levels of several important inflammatory markers in patients with type 2 diabetes and coronary heart disease.en_US
dc.description.sponsorshipAbant Izzet Baysal University, Turkey [2006/245]en_US
dc.description.sponsorshipThe study was funded by grands from Abant Izzet Baysal University, Turkey (Project Number: 2006/245)en_US
dc.identifier.endpage34en_US
dc.identifier.issn1301-2193
dc.identifier.issue2en_US
dc.identifier.startpage31en_US
dc.identifier.urihttps://hdl.handle.net/20.500.12491/13277
dc.identifier.volume14en_US
dc.identifier.wosWOS:000217309300003en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.language.isoenen_US
dc.publisherGalenos Yayinciliken_US
dc.relation.ispartofTurkish Journal of Endocrinology And Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmzYK_20240925en_US
dc.subjectAtorvastatinen_US
dc.subjecthsCRPen_US
dc.subjectinterleukin-6en_US
dc.subjectTNF-alphaen_US
dc.subjecttype 2 diabetesen_US
dc.titleIntensive Lipid Reduction and Proinflammatory Markers in the MODEST Studyen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu